Cagrilintide is a long-acting amylin receptor agonist developed as a synthetic analog of the natural hormone amylin, which is co-secreted with insulin by pancreatic beta cells. It is structurally modified to increase half-life and receptor affinity, enabling once-weekly dosing. Cagrilintide is primarily investigated for its appetite-suppressing and weight-reducing properties, often in combination with GLP-1 receptor agonists like semaglutide for synergistic metabolic effects.

Benefits:

• Appetite Suppression: Reduces food intake by slowing gastric emptying and enhancing satiety signals via the brainstem and hypothalamus.
• Weight Loss Enhancement: When used alone or in combination (e.g., with semaglutide), leads to significant and sustained body weight reductions.
• Complementary Mechanism: Works via the amylin receptor, distinct from GLP-1 and GIP pathways, allowing for powerful synergistic combinations.
• Improved Metabolic Markers: May reduce waist circumference, body fat percentage, and improve cardiometabolic risk factors.
• Weekly Dosing: Long-acting formulation provides consistent effects with convenient administration.